National Institute of Allergy & Infectious Diseases (NIAID)
31 Center Drive MSC 2520
Building 31, Room 7A-50
220 articles with National Institute of Allergy & Infectious Diseases (NIAID)
IDT Biologika Awarded New Task Order in the Scope of 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases
IDT Biologika announced that the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, an agency of the United States Department of Health and Human Services, has awarded the company a new Task Order within the 10-year Indefinite Delivery, Indefinite Quantity contract no. HHSN272201800011I to provide process development activities and production of a vaccine against the Respiratory Syncytial Virus.
The Phase 1 clinical study is expected to begin enrollment this year and is being funded by the National Institute of Allergy and Infectious Diseases, an institute within the National Institutes of Health
Porton Biopharma Ltd has announced that it has signed a modification to its contract with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases to advance a next generation intra-nasal anthrax vaccine into the clinical-trial phase.
Theratechnologies Inc. is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease in HIV were published in the Lancet HIV.
The award is through the Broad Agency Announcement (BAA) program to advance Versatope's universal influenza vaccine candidate.
Progentec Diagnostics Awarded SBIR Fast-Track Grant to Develop Immune Mediator-Based Blood Tests for Clinical Disease Activity in Lupus (SLE)
In-development laboratory tests will inform concurrent and future clinical disease activity
Precision Medicine Studies Underway to Enable Dynamic Monitoring of Disease Progression and Response to Treatment
Bolder BioTechnology Receives NIH Grant to Advance Development of Novel Treatments for Acute Radiation Syndrome
The grant is a joint research project between Bolder BioTechnology and Indiana University School of Medicine (Indianapolis, IN)
LHF-535, Kineta's lead biodefense asset, is a novel once-daily oral antiviral drug currently being evaluated in Phase 1 safety trials in healthy volunteers.
The Centers for Disease Control and Prevention (CDC) estimates that approximately 300,000 people will be infected with Lyme disease each year in the United States.
LamdaGen and Arisan Therapeutics Receive a $2 Million NIH SBIR Phase II Grant to Develop a Dual Rapid Point-of-Care Test for Acute Dengue and Zika Viral Infections
The L’AuRa platform enables robust diagnostic testing that is simple, compact and cost effective with no moving parts.
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology
NIAID to Study Use of ENHANZE® Technology with Broadly Neutralizing Antibodies for Development of New HIV Treatments
Five-year, $22 million grant to develop antibody-based therapies against four highly lethal viruses for which there are no approved vaccines or treatments.
IDT Biologika Awarded 10-Year NIH Contract to Manufacture Vaccines and Biologics for Infectious Diseases
The total funding could be up to $80 million over the course of the contract if all project milestones are met.
TechnoVax, Inc. has received a two-year $1,481,000 SBIR-II grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH).
Emergent BioSolutions, headquartered in Gaithersburg, Maryland, inked a deal to buy PaxVax, based in Redwood City, California, for $270 million in cash.
Lupus Foundation of America and the National Institute of Allergy and Infectious Diseases to co-fund an innovative clinical study that could generate progress towards new treatments
NIAID Director Dr. Anthony Fauci to discuss progress made in the development of a universal flu vaccine at National Press Club Headliners Luncheon July 18
This past year's flu season killed more children than any other non-pandemic year on record, according to data released by the Centers for Disease Control and Prevention (CDC) earlier this year.
The 2017/2018 influenza season was considered one of the worst, made more so by the ineffectiveness of the season’s flu vaccine. The FDA is focusing partially on simply determining why this year’s flu vaccine missed the mark.